美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · BCAX近 30 天 1 則 · 第 1 / 1 頁
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
- Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX)
- Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
- Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary
- Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances
- Bicara Therapeutics Q2 Earnings Call Highlights
- Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
- Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
- Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
- What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
- Bicara (BCAX) Q4 2025 Earnings Transcript
- Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
- Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。